. 2014 Jan 10;92(3):162–170. doi: 10.2471/BLT.13.122523

Table 6. Percentage change in incremental cost^a per woman of Option B+^b relative to Option B^c over 5 years postpartum, by CD4+ cell count and for fixed-dose and non-fixed-dose pricing of antiretrovirals.

Breastfeeding status and duration	CD4+ count 350–500 cells/µl			CD4+ count > 500 cells/µl
Breastfeeding status and duration	Incremental cost, non-fixed-dose pricing (US$)	Incremental cost, fixed-dose pricing (US$)	Percentage change	Incremental cost, non-fixed-dose pricing (US$)	Incremental cost, fixed-dose pricing (US$)	Percentage change
Breastfeeding
12 months	255	277	9	808	853	6
18 months	–	–	9	707	746	6
24 months	–	–	9	606	640	6
No breastfeeding	154	170	10	1010	1066	6

^a All costs are in 2011 United States dollars (US$).

^b Option B+ comprises a triple antiretroviral (ARV) regimen initiated during pregnancy and continued for life.

^c Option B comprises a maternal triple ARV regimen, typically consisting of the recommended first-line antiretroviral therapy, during pregnancy and throughout breastfeeding, in combination with 6 weeks of daily nevirapine for the infant, regardless of infant feeding method.

Table 6. Percentage change in incremental costa per woman of Option B+b relative to Option Bc over 5 years postpartum, by CD4+ cell count and for fixed-dose and non-fixed-dose pricing of antiretrovirals.

Table 6. Percentage change in incremental cost^a per woman of Option B+^b relative to Option B^c over 5 years postpartum, by CD4+ cell count and for fixed-dose and non-fixed-dose pricing of antiretrovirals.